TITLE:
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

CONDITION:
Breast Cancer

INTERVENTION:
Ixabepilone

SUMMARY:

      The purpose of this research study is to assess the response rate of the investigational
      drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to
      an anthracycline, a taxane, and capecitabine.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients must have received all 3 drugs- an anthracycline, taxane, and capecitabine
             (alone or in combination) and be resistant

          -  No more than 3 prior chemotherapy regimens in the metastatic setting

          -  Must have at least one target lesion that is radiographically measurable

          -  Good performance status

          -  No history of or current brain or leptomeningeal disease
      
